Search results for "SCHEDULE"

showing 10 items of 567 documents

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms

2016

SummaryAim The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. Methods Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple…

AdultMalemedicine.medical_specialtyCommon ColdInfectious DiseaseIbuprofenNonprescription DrugsPharmacy030226 pharmacology & pharmacyDrug Administration Schedule03 medical and health sciences0302 clinical medicineExpedited Clinical TrialSurveys and QuestionnairesInternal medicinemedicineHumans030223 otorhinolaryngologyNosePain Measurementbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommon coldmultiple regression analysisGeneral MedicinePseudoephedrinemedicine.diseaseIbuprofenPseudoephedrinesymptom scoreNasal decongestantNasal DecongestantsTreatment Outcomemedicine.anatomical_structureAnesthesiaJoint painDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugCombination drugInternational Journal of Clinical Practice
researchProduct

The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

2018

Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD. Methods All consecutive patients with loss of response to anti-TNFα monotherapy despite an intensive dose optimization who added an IM from October 2014 to October 2016 were entered into a prospective database. Results Among 630 patients treated with anti-TNFα agents during the study period, 46 (7.3%) added an IM. A total of 31 patie…

AdultMalemedicine.medical_specialtyDatabases FactualCombination therapyGastroenterologyInflammatory bowel diseaseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdalimumabHumansImmunology and AllergyProspective StudiesAdverse effectbiologyTumor Necrosis Factor-alphabusiness.industryRemission InductionC-reactive proteinAdalimumabGastroenterologyAntibodies MonoclonalMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseInfliximabGolimumabInfliximabDiscontinuationC-Reactive ProteinTreatment Outcome030220 oncology & carcinogenesisbiology.proteinDrug Therapy CombinationFemale030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugInflammatory Bowel Diseases
researchProduct

Mealtime versus nighttime acid inhibition

1992

This study was carried out in order to compare the effects of mealtime and bedtime regimens of ranitidine on gastric acidity. Fifteen duodenal ulcer patients in clinical remission were randomized to receive in single-blind fashion either placebo, ranitidine 300 mg at night (2200 hr) or ranitidine 150 mg three times a day given before each of the three daily meals (1800, 0800 and 1200 hr). Over 24 hr, the two active treatments produced a significantly greater acid inhibition than placebo, while the single daily regimen was superior to the three times a day regimen of ranitidine in terms of both rise in pH values (P less than 0.001) and duration of action expressed as time spent above 3.0 pH …

AdultMalemedicine.medical_specialtyEveningPhysiologyRanitidinePlaceboBedtimeGastroenterologyDrug Administration ScheduleRanitidineEatingHistamine H2 receptorInternal medicinemedicineHumansSingle-Blind MethodCircadian rhythmGastric Acidity Determinationbusiness.industryGastroenterologyGastric Acidity DeterminationMiddle AgedCircadian RhythmRegimenEndocrinologyDuodenal UlcerFemalebusinessmedicine.drugDigestive Diseases and Sciences
researchProduct

Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins.

2006

The aim of this study was to evaluate different durations of treatment in patients with calf venous thrombosis (CVT) involving 1 or more deep veins. The authors studied 2 groups of patients with postsurgical CVT diagnosed by echo-color Doppler. The first group consisted of 68 patients with CVT involving a single vein, and the second group consisted of 124 patients with CVT involving 2 or more veins. Immediately after diagnosis, all patients were treated with nadroparin calcium and sodium warfarin. Heparin treatment was withdrawn after 5–6 days of treatment, when the international normalized ratio (INR) was stabilized between 2 and 3. Each group was divided into 2 subgroups receiving antico…

AdultMalemedicine.medical_specialtyFemoral vein030204 cardiovascular system & hematologyDrug Administration ScheduleLesion03 medical and health sciences0302 clinical medicinePostoperative ComplicationsMedicineHumans030212 general & internal medicineThrombusUltrasonography Doppler ColorVeinAgedVenous ThrombosisLegbusiness.industryAnticoagulantsNadroparinHeparinMiddle Agedmedicine.diseaseNadroparin calciumSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiacardiovascular systemFemaleWarfarinmedicine.symptomCardiology and Cardiovascular MedicinebusinessSurgical patientsmedicine.drugAngiology
researchProduct

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

2008

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineRibavirinmedicineHumansProspective StudiesRapid Virologic Responsegenotype 1Hepatologybusiness.industryRibavirinStandard treatmentInterferon-alphavirus diseasesHepatitis CMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalSurgeryTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalehepatitis Cbusiness
researchProduct

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open st…

1992

In vitro studies on the effects of dexamethasone on human synovial cells have shown that with high concentrations of the steroid in the culture medium cellular activity was completely blocked whereas with low concentrations (10(-6)M), cellular density decreased but there was an increase in the synthesis of RNA, DNA, protein and hyaluronic acid. These data, coupled with clinical experience of using intra-articular hyaluronic acid to treat patients with osteoarthritis of the knee, prompted the investigators to carry out an open, randomized study of the use of very small doses of dexamethasone in association with hyaluronic acid in 40 osteoarthritic patients. Twenty patients received a weekly …

AdultMalemedicine.medical_specialtyKnee Jointmedicine.drug_classmedicine.medical_treatmentSodium hyaluronatePainOsteoarthritismedicine.disease_causeDexamethasoneDrug Administration ScheduleInjections Intra-ArticularWeight-bearinglaw.inventionchemistry.chemical_compoundRandomized controlled triallawOsteoarthritisHyaluronic acidmedicineHumansHyaluronic AcidDexamethasoneAgedPain MeasurementChemotherapybusiness.industryDrug SynergismGeneral MedicineMiddle Agedmedicine.diseaseSurgeryMolecular WeightchemistryAnesthesiaCorticosteroidFemalebusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

2009

<i>Background:</i> Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH. <i>Methods:</i> Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study. <i>Results:</i> All patients reported …

AdultMalemedicine.medical_specialtyLong term treatmentC1 inhibitor deficiencyImmunologyBradykininGastroenterologyDrug Administration ScheduleC1-inhibitorEdemaInternal medicineHumansImmunology and AllergyMedicineProspective Studiesskin and connective tissue diseasesBradykinin Receptor AntagonistsC1 esterase inhibitor deficiencyAgedbiologyAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSurgeryHereditary angioedemaImmunologybiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinInternational Archives of Allergy and Immunology
researchProduct

A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.

2002

Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects with UFT have been demonstrated in vitro. A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors.UFT and folinic acid were applied at 300 mg/m2/day and 90 mg/day, respectively, on days 1-28, repeated on day 36. Paclitaxel was applied on days 1, 8, 15 and 22 of each cycle. The starting dose of paclitaxel was 50 mg/m…

AdultMalemedicine.medical_specialtyMaximum Tolerated DosePaclitaxelmedicine.medical_treatmentLeucovorinAdministration OralPharmacologyTegafurGastroenterologyDrug Administration Schedulechemistry.chemical_compoundFolinic acidLeukocytopeniaOral administrationInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedTegafurChemotherapyDose-Response Relationship Drugbusiness.industryHematologyMiddle AgedSurvival AnalysisTreatment OutcomeOncologyPaclitaxelchemistryFluorouracilToxicityFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction…

2005

Desired adjustment of methadone dose, perceived participation in dosage regulation, and satisfaction with methadone treatment centres were assessed in a sample of opioid-dependent patients from the Valencia Region (eastern Spain). An independent interviewer asked 278 consecutively arriving patients to answer the survey, and 165 (59.4%) completed it. Adjustment of methadone dose was assessed with a -10 to +10 visual analogue scale (VAS-MD); participation in methadone dose regulation, with specific questions; and patient satisfaction, with the Verona Service Satisfaction Scale for methadone treatment (VSSS-MT). The methadone dose (mg/d) prescribed by physicians was (mean+/-S.D.) 68.0+/-30.4. …

AdultMalemedicine.medical_specialtyMethadone maintenanceAdolescentVisual analogue scalemedia_common.quotation_subjectPersonal SatisfactionToxicologyDrug Administration ScheduleHeroinPatient satisfactionDose adjustmentInternal medicinemedicineHumansPharmacology (medical)Patient participationPsychiatrymedia_commonPharmacologybusiness.industryHeroin DependenceAddictionMiddle AgedOpioid-Related DisordersPsychiatry and Mental healthSpainFemaleHealth Services ResearchPatient ParticipationbusinessAttitude to HealthMethadonemedicine.drugMethadoneDrug and alcohol dependence
researchProduct